These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16465944)

  • 1. [New obesity and metabolic syndrome treatment: rimonabant].
    Makoundou V; Golay A
    Rev Med Suisse; 2006 Jan; 2(47):41-5. PubMed ID: 16465944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
    Kakafika AI; Mikhailidis DP; Karagiannis A; Athyros VG
    J Clin Pharmacol; 2007 May; 47(5):642-52. PubMed ID: 17392496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
    Christopoulou FD; Kiortsis DN
    J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
    Cox SL
    Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
    Andrikopoulos GK; Tzeis S
    Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecule of the month. Rimonabant hydrochloride.
    Drug News Perspect; 2004; 17(6):403. PubMed ID: 15334190
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
    Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.
    Maynadier M; Basile I; Gary-Bobo M
    Drug Discov Today; 2009 Feb; 14(3-4):192-7. PubMed ID: 18951999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome.
    Russell JC; Kelly SE; Diane A; Wang Y; Mangat R; Novak S; Vine DF; Proctor SD
    Am J Physiol Gastrointest Liver Physiol; 2010 Aug; 299(2):G507-16. PubMed ID: 20508159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.